Type I interferons have been suspected for decades to have a crucial role in the
pathogenesis of systemic lupus erythematosus (SLE). Evidence has now overturned several …

Background Type I interferons (IFN-I) contribute to a broad range of rheumatic and
musculoskeletal diseases (RMDs). Compelling evidence suggests that the measurement of …

Background Systemic lupus erythematosus (SLE) is a multisystemic, chronic inflammatory
disease characterized by destructive systemic organ involvement, which could cause the …

Objectives Systemic lupus erythematosus (SLE) is a chronic autoimmune condition with
heterogeneous presentation and complex aetiology where DNA methylation changes are …

Background Lymphocyte activating 3 (LAG3, LAG-3, CD223) is a promising target for
immune checkpoint inhibition in clear cell renal cell carcinoma (KIRC). The aim of this study …

Background Diffuse large B‐cell lymphoma (DLBCL) incidence is higher in systemic lupus
erythematosus (SLE) patients than the general population, but the molecular mechanisms …

Objectives To identify novel DNA methylation sites significant for rheumatoid arthritis (RA)
and comprehensively understand their underlying pathological mechanism. Methods We …

Autoimmune rheumatic diseases pose many problems that have, in general, already been
solved in the field of cancer. The heterogeneity of each disease, the clinical similarities and …

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the
breakdown of immune tolerance leading to excessive inflammation and tissue damage …

Although it has been proved that the epigenetic modification of DNA and histones is
involved in the pathogenesis of systemic lupus erythematosus (SLE), there is no study to …